Toronto, Canada
Vasomune Therapeutics, Inc., founded in 2014, is a biotech innovator based in Canada. The company's slogan, "Biopharmaceutical leaders developing the next generation of medicine to normalize host vascular response," encapsulates its commitment to addressing vascular dysfunctions. This private biotechnology firm is making significant progress in areas like Biotechnology, Health Care, and Life Sciences.
Vasomune's pioneering work revolves around activating the Tie2 pathway to develop therapeutics for conditions such as Acute Respiratory Distress Syndrome, Acute Kidney Injury, sepsis, and Cardiopulmonary Bypass. Its lead drug candidate targets signaling molecules crucial in regulating vascular responses, effectively reducing vascular leaks and proinflammatory factors.
The company's latest funding of $2.80M, a grant received in November 2021, was provided by the National Research Council of Canada Industrial Research Assistance Program, indicating promising support for its cutting-edge research and potential to revolutionize treatment paradigms.
